Precipio (NASDAQ:PRPO – Get Free Report) is projected to post its Q3 2026 results after the market closes on Tuesday, November 10th. Analysts expect Precipio to post earnings of ($2.00) per share and revenue of $1.68 million for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 5:00 PM ET.
Precipio (NASDAQ:PRPO – Get Free Report) last announced its quarterly earnings data on Friday, August 14th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.00) by $1.88. Precipio had a negative net margin of 4.47% and a negative return on equity of 8.49%. The business had revenue of $7.02 million for the quarter, compared to analysts’ expectations of $1.68 million.
Precipio Price Performance
Shares of PRPO opened at $18.62 on Monday. The firm has a 50 day simple moving average of $23.41 and a two-hundred day simple moving average of $24.79. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.77 and a quick ratio of 1.56. Precipio has a one year low of $17.79 and a one year high of $33.63. The company has a market cap of $33.33 million, a P/E ratio of -29.09 and a beta of 1.45.
Analyst Ratings Changes
Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Precipio in a research note on Thursday, October 15th. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, Precipio presently has a consensus rating of “Sell”.
Check Out Our Latest Report on Precipio
Precipio Company Profile
Precipio, Inc (NASDAQ: PRPO) is a biotechnology and medical diagnostics company focused on improving the diagnosis of cancer and other complex diseases. The company combines specialized pathology expertise with laboratory testing and diagnostic technologies intended to help physicians identify disease accurately and support treatment decisions.
Precipio provides clinical laboratory services in areas including hematopathology, cytogenetics and molecular diagnostics. Its work is particularly focused on blood cancers and other hematologic disorders, where accurate classification can be challenging.
Read More
- Five stocks we like better than Precipio
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
- After the Midterms, Which of These 3 Defense ETFs Looks Strongest?
- The Ugly Truth Behind SoundHound’s Q3 Results
Receive News & Ratings for Precipio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precipio and related companies with MarketBeat.com's FREE daily email newsletter.
